Keros Therapeutics, Inc. Common Stock KROS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:17:44.393Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:08.470592661Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T14:14:49.058937+00:00
Keros Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.90 | 104.0% | 63.2% | |||
| 25Δ | 13.98 | 101.1% | 54.2% | |||
| 30Δ | 13.05 | 98.2% | 45.3% | |||
| 35Δ | 12.13 | 95.2% | 36.4% | |||
| 40Δ | 11.20 | 92.3% | 27.4% | |||
| 45Δ | 10.28 | 89.4% | 18.5% | |||
| 50Δ | 9.71 | 93.2% | 14.8% | |||
| 55Δ | 9.31 | 100.1% | 13.4% | |||
| 60Δ | 8.90 | 106.9% | 12.0% | |||
| 65Δ | 8.49 | 113.7% | 10.6% | |||
| 70Δ | 8.08 | 120.5% | 9.2% | 10.49 | 48.9% | 2.1% |
| 75Δ | 7.67 | 127.4% | 7.8% | 11.09 | 56.1% | 1.8% |
| 80Δ | 11.68 | 63.3% | 1.4% | |||
20Δ
- Pseudo strike
- 14.90
- IV
- 104.0%
- B/E move
- 63.2%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 13.98
- IV
- 101.1%
- B/E move
- 54.2%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 13.05
- IV
- 98.2%
- B/E move
- 45.3%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 12.13
- IV
- 95.2%
- B/E move
- 36.4%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 11.20
- IV
- 92.3%
- B/E move
- 27.4%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 10.28
- IV
- 89.4%
- B/E move
- 18.5%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 9.71
- IV
- 93.2%
- B/E move
- 14.8%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 9.31
- IV
- 100.1%
- B/E move
- 13.4%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 8.90
- IV
- 106.9%
- B/E move
- 12.0%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 8.49
- IV
- 113.7%
- B/E move
- 10.6%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 8.08
- IV
- 120.5%
- B/E move
- 9.2%
- Pseudo strike
- 10.49
- IV
- 48.9%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- 7.67
- IV
- 127.4%
- B/E move
- 7.8%
- Pseudo strike
- 11.09
- IV
- 56.1%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.68
- IV
- 63.3%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 141.68% | |
| 144.61% | |
| 148.68% | |
| 175.53% | |
| 170.04% | |
| 178.47% | |
| 192.96% | |
| 136.02% | |
| 140.30% | |
| 131.18% | |
| 135.61% | |
| 140.68% | |
| 144.35% | |
| 151.41% | |
| 155.22% | |
| 155.00% | |
| 156.87% | |
| 157.32% |
Biotechnology
KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent…
More →KRYS
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company…
More →KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego,…
More →KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins…
More →KYTX
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health challenges. Employing…
More →KZIA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
More →